Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID‐19 in New Zealand
Open Access
- 7 January 2021
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 73 (5), 896-897
- https://doi.org/10.1002/art.41643
Abstract
The rapid spread of coronavirus disease 2019 (COVID‐19) brought into sharp focus the conundrum of how to balance evidence‐based prescribing vs empiric treatment with repurposed drugs for a pandemic with a high mortality risk. Initial attention focused on hydroxychloroquine/chloroquine due to evidence of in vitro activity against the novel coronavirus SARS‐CoV‐2,1 yet the external validity of these data was limited by knowledge that in vitro antiviral activity did not equate to efficacy in randomised controlled trails (RCTs) of hydroxychloroquine/chloroquine treatment for influenza, dengue, chikungunya, and human immunodeficiency virus infection.1This publication has 4 references indexed in Scilit:
- Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Successful Elimination of Covid-19 Transmission in New ZealandThe New England Journal of Medicine, 2020
- Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United StatesJAMA, 2020
- Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidenceTherapies, 2020